EMA’s human medicines committee (CHMP) has accepted a brand new web site to fabricate Vaxzevria (beforehand COVID-19 Vaccine AstraZeneca) completed product. The positioning, operated by WuXi Biologics, is situated in Leverkusen, Germany.
Along with this new manufacturing facility, the CHMP has additionally given a constructive opinion to scale up manufacturing to triple the batch measurement of completed product at a web site operated by Amylin Ohio in West Chester Township, Ohio, the US.
These modifications are anticipated to assist the continued provide of Vaxzevria within the European Union and donations to 3rd international locations by means of the COVID-19 Vaccines International Entry (COVAX) initiative.